Silo Pharma Enters Exclusive Global License for Alzheimer’s Therapeutic
DENVER, Colo., Jul 16, 2024 (247marketnews.com)- Silo Pharma, Inc. (Nasdaq:SILO) stated that it enhanced its intellectual property portfolio by securing an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer’s drug SPC-14, for which Silo intends to utilize the FDA’s streamlined 505(b)(2) pathway for SPC-14 to shorten clinical timelines and reduce drug development costs.
Silo’s CEO, Eric Weisblum, commented, “In our view, our exclusive license for SPC-14 gives us the potential to meet a large unmet medical need. If approved, we believe SPC-14 could bring hope and relief for many families and patients. Early pre-clinical studies have shown stress reduction and cognitive improvement.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (SILO)
- Small Caps Aim Big as Digital Asset Strategies Spark Momentum
- MoBot’s Stock Market Highlights – 09/23/25 08:00 AM
- Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
- 24/7 Market News Snapshot 23 September, 2025 – Silo Pharma, Inc. Common Stock (NASDAQ:SILO)
- Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy